Therapeutic Apheresis
Customize your policy alerts
Sign up for CareFirst Policy 7.01.030 alerts
Get alerted when Policy 7.01.030 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity indications and experimental/investigational exclusions for therapeutic apheresis procedures; CareFirst adopts MCG Care Guidelines® for clinical criteria and requires checking member contract and prior authorization when applicable.
Update 2025: CareFirst adopted the position of MCG Care Guidelines® and retired the policy; literature review March 2025–October 2025 did not change conclusions.
Update 2024: MCG updates resulted in adding age-related macular degeneration and Refsum's disease as medically necessary indications and classifying other diagnoses as experimental/investigational.
Multiple prior updates (2019, 2017, 2015, 2013, 2010, 2008) modified or clarified medically necessary indications over time (examples: addition of NMDA receptor antibody encephalitis in 2019; ABO incompatible HPC transplantation and ANCA vasculitis in 2010).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.